REG3α for protection of oxygen-sensitive Gram-positive bacteria

By using Reg3α polypeptide to protect oxygen-sensitive Gram-positive bacteria, the problem of intestinal microbiota imbalance was solved, the resistance to intestinal inflammation was significantly improved, and the integrity of the intestinal barrier was maintained, and microbiota-related diseases were prevented or treated. .

CN112004549BActive Publication Date: 2024-12-03THE HEALTHY AGING CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880055594.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-07-13
Filing Date
2018-07-13
Publication Date
2024-12-03
Estimated Expiration
2038-07-13

AI Technical Summary

Technical Problem

The prior art is difficult to effectively protect and promote the growth of oxygen-sensitive Gram-positive bacteria, resulting in imbalance in the intestinal microbiome and the occurrence of related diseases.

Method used

Using Reg3α polypeptide, which contains specific amino acid sequences, protects oxygen-sensitive Gram-positive bacteria by oral administration, promotes their growth and survival, and restores the balance of the gut microbiota.

Benefits of technology

Significantly improve the host's resistance to intestinal inflammation, reduce inflammation, maintain intestinal barrier integrity, and prevent or treat microbiota-related diseases and disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0002392977600000011
    Figure HDA0002392977600000011
  • Figure HDA0002392977600000021
    Figure HDA0002392977600000021
  • Figure HDA0002392977600000031
    Figure HDA0002392977600000031
Patent Text Reader

Abstract

The present invention relates to a Reg3α polypeptide (also known as hepatocarcinoma-intestinal-pancreatic / pancreatitis-associated protein (HIP / PAP)) for protecting oxygen-sensitive Gram-positive bacteria, a composition comprising the polypeptide and its use. The inventors have demonstrated that an increase in the concentration of hReg3α lectin in the lumen of the gastrointestinal tract (GIT) of hReg3α transgenic mice induces significant changes in the composition of the intestinal microbiota and significantly improves the host's resistance to intestinal inflammation. hReg3α has potent antioxidant activity on intestinal epithelial cells during colitis, and in particular ROS scavenging activity, in particular by promoting the survival of hyperoxygen-sensitive bacteria. The inventors have also demonstrated that, after antibiotic treatment, hReg3α transgenic mice are better resistant to DSS-induced colitis. Therefore, the present invention relates to a Reg3α polypeptide for protecting oxygen-sensitive Gram-positive bacteria, in particular Ruminococcus family, such as Faecalibacterium prausnitzii and / or Lachnospiraceae family, such as enteric Roseburia; a pharmaceutical composition comprising the polypeptide and its use; and the use of this polypeptide for promoting the in vitro growth of oxygen-sensitive Gram-positive bacteria. The Reg3α polypeptide can be used to prevent or treat microbiota-related diseases and / or disorders, in particular selected from inflammatory bowel disease (IBD), colitis, gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal cancer, metabolic syndrome and obesity, diabetes, liver disease, allergic diseases, neurodegenerative diseases and psychological disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a polypeptide for protecting oxygen-sensitive Gram-positive bacteria, a composition comprising the polypeptide and use thereof, and use of the polypeptide for promoting the in vitro growth of oxygen-sensitive Gram-positive bacteria. [Background technology]

[0002] In mammals and especially humans, microbiota includes microorganisms such as bacteria, viruses, fungi and archaea (single-cell microorganisms), and can be found on the skin (including dermis and dermal adipose tissue), in the mouth, nose, respiratory tract, digestive tract and reproductive system. Microbiota not only has a symbiotic relationship with its host, but also has a mutually beneficial relationship with its host because it preserves organs, tissues and immune homeostasis locally and remotely. Microbiota performs several tasks, including nutritional functions (epithelial cell renewal, intestinal motility, intestinal wall structure, mucosal maturation, thickness, structure, etc.), metabolic functions (fat deposition, digestion, energy metabolism control) and also defense functions (antimicrobial immunity, Paneth cell differentiation, foreign bacteria or pathogen barriers), and under normal circumstances, they will not cause disease or disorder to the host. Under abnormal conditions (such as inflammation), there is an imbalance in the microbiota, and the microbiota can affect host defense and immunity, and then may become pathogenic and cause the start or deterioration of disorder and / or disease. This is particularly evident in the digestive tract microbiota.

[0003] Our gut microbiota contains tens of trillions of microorganisms, including at least 1,000 different species of known bacteria with more than 3 million genes. The total weight of the microbiota can be as high as 2kg. One-third of our gut microbiota is common to most people, while two-thirds is unique to each of us. In mammals, and especially in humans, the gut microbiota is a community of microorganisms that inhabits the length and breadth of the gastrointestinal tract. The composition of this microbial community is host-specific. Each person's gut microbiota can undergo endogenous and exogenous changes. It is also called the human flora, microbiome, microbiota, or gut flora. In humans, the gut microbiota is established one to two years after birth, and by that time, the intestinal epithelium and intestinal mucosal barriers that it secretes have co-developed in a way that tolerates and even supports the gut microbiota, and also provides an effective barrier to pathogenic organisms. The gut microbiota evolves from an immature and unstable ecosystem in infancy to a more complex and stable ecosystem in adulthood. Humans and the gut microbiota are in a symbiotic relationship, and the gut microbiota interacts with its host through bidirectional signaling, connecting it to extraintestinal organs (brain, liver) and influencing their health and metabolism, which may lead to metabolic diseases.

[0004] The gut microbiota plays many important roles, including digestion, metabolism, nutrient extraction, vitamin synthesis, protection against pathogen colonization, and regulation of the immune system.

[0005] In the gut microbiome of a healthy person, there is a balance between beneficial bacteria and potentially harmful or pathogenic bacteria. Health problems begin when the gut microbiome becomes unbalanced, for example due to antibiotic treatment.

[0006] If the amount of harmful bacteria increases greatly, various symptoms and pathological conditions may occur. This imbalance is called dysbiosis or dysbacteriosis. It refers to an imbalance in the number or type of microbial flora that have colonized the intestine. This is most common in the digestive tract, but it can also occur on any exposed surface or mucosa of the human body where bacteria are present and active. Studies aimed at identifying individual bacterial members of the microbiota with the ability to promote immune maturation or inflammation have repeatedly identified similar species or groups of organisms, such as Prevotellaceae bacteria and adherent invasive Escherichia coli (AIEC). These microorganisms are named pathobionts to describe their potential pathogenic effects on the host. Although pathobionts coexist in healthy, immunocompetent hosts without overt disease and significantly support the maturation of the immune system, in some cases their effects can trigger inflammation, autoimmunity and promote the development of clinical diseases. Dysbiosis can affect digestion, the absorption of nutrients, the production of vitamins and control the growth of harmful microorganisms. Many factors, such as changes in dietary habits or the use of antibiotics, can affect the delicate microbial balance and thus lead to dysbiosis. Researchers believe it may play a role in disorders such as inflammatory bowel disease (IBD), chronic fatigue, obesity, or certain cancers.

[0007] Alterations or changes in the composition and / or biodiversity of the intestinal microbiota have been shown to be associated with microbiota-related diseases and disorders, including inflammatory bowel disease (IBD), gastrointestinal infections, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal cancer, non-gastrointestinal cancer (Pevsner-Fischer, Role of the microbiome in non-gastrointestinal cancers, World J Clin Oncol. 2016; 7(2): 200–213), metabolic syndrome and obesity, acute and chronic liver disease, allergic diseases, autoimmune diseases (Kim D. Gut microbiota in autoimmunity: potential for clinical applications. Arch Pharm Res. 2016), cystic fibrosis (Nielsen S, Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Sci Rep. 2016 May 4; 6: 24857; Duytschaever G. Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. J Cyst Fibros. 2013; 12(3): 206-15), atopic dermatitis and neurological diseases such as autism (Ianiro et al., Curr Drug Targets 2014; 15(8): 762-70), anxiety, depression and chronic pain (Mayer, Gut Microbes and the Brain: Paradigm Shift in Neuroscience. The Journal of Neuroscience, 2014, 34(46): 15490-15496).

[0008] Dysbiosis can be defined as an alteration in the state of the microbiota that occurs during disease compared to the compositional and functional homeostasis of healthy individuals. Currently, dysbiosis is considered a hallmark of altered microbiome-host crosstalk and a major target for strategies aimed at restoring or maintaining functional homeostasis of the intestine. Despite the obvious limitations imposed by the composition and diversity of the microbiota, dysbiosis is suspected to be a key pathogenic factor in a variety of intestinal and extra-intestinal diseases. However, microbiota imbalance, including an increase in microbial biomass at the mucosal level, an increase in the proportion of immuno-aggressive bacteria (mainly Gram-negative) and a decrease in the proportion of conversely immuno-protective bacteria (mainly Gram-positive), triggers a vicious cycle of auto-amplification.

[0009] Modulation of the intestinal microbiota in the management of microbiota-associated diseases and disorders is a promising approach for their treatment and / or prevention. Prior art relates to the use of probiotics, prebiotics, antimicrobials, bariatric surgery and weight loss strategies (Omotayo et al., Int J Mol Sci. 2014 Mar; 15(3): 4158–4188).

[0010] The human secreted C-type lectin Reg3α, also known as hepatocarcinoma-intestinal-pancreatic / pancreatitis-associated protein (HIP / PAP), is a 16 kDa carbohydrate-binding protein that exhibits anti-inflammatory activity in many eukaryotic cell types and tissues. It is expressed in Paneth cells and neuroendocrine cells of the small intestine under physiological conditions and in the large intestine in response to infection and inflammation.

[0011] Truncated variants of Reg3α are known to be anti-inflammatory and / or antibacterial agents (US 7,923,014 and US 8,212,007).

[0012] The inventors have surprisingly found that, contrary to known antimicrobial activity, the Reg3α polypeptide allows the protection of oxygen-sensitive Gram-positive bacteria. The present invention therefore relies on the fact that the polypeptide Reg3α has a protective effect on oxygen-sensitive Gram-positive bacteria and in particular on beneficial commensals of the intestinal microbiota. [Summary of the invention]

[0013] The present invention relates to a Reg3α polypeptide for protecting oxygen-sensitive Gram-positive bacteria, which comprises an amino acid sequence of SEQ ID NO: 4 or a sequence at least 85% identical thereto.

[0014] Also provided is a pharmaceutical composition for oral or transmucosal administration, comprising a Reg3α polypeptide comprising an amino acid sequence of SEQ ID NO: 4 or a sequence at least 85% identical thereto, and at least one pharmaceutically acceptable excipient.

[0015] The present invention also relates to the use of the above composition for preventing or treating microbiota-related diseases and / or disorders.

[0016] According to another aspect, the present invention relates to the use of a Reg3α polypeptide comprising the amino acid sequence of SEQ ID NO: 4 or a sequence at least 85% identical thereto for promoting the in vitro growth of oxygen-sensitive Gram-positive bacteria.

[0017] Also provided is the use of a Reg3α polypeptide comprising the amino acid sequence of SEQ ID NO: 4 or a sequence at least 85% identical thereto for preparing a food.

[0018] Description of the Invention

[0019] The inventors have demonstrated that increased concentrations of hReg3α lectin in the lumen of the gastrointestinal tract (GIT) of transgenic mice induce significant changes in the composition of the intestinal microbiota and significantly improve host resistance to intestinal inflammation. In fact, hReg3α transgenic mice exposed to DSS (dextran sulfate sodium) showed almost no signs of colitis, maintained a tight mucosal barrier and achieved complete survival. During colitis, hReg3α has a potent antioxidant activity on intestinal epithelial cells, and in particular the ROS scavenging activity of recombinant human Reg3α (rcReg3α) acts on prokaryotic cells, in particular by promoting the survival of hyperoxia-sensitive bacteria.

[0020] The microbial changes exhibited by homozygous hReg3α transgenic mice under steady-state and inflammatory conditions mainly include enrichment of Clostridiales (Ruminococcaceae, Lachnospiraceae) and depletion of Bacteroidetes (Prevotellaceae). Since repeated intravenous administration of rcReg3α did not improve DSS-induced colitis in WT mice, systemic anti-cologenic effects were abandoned. The inventors demonstrated that hReg3α provides protection against oxidative stress for both the intestinal epithelium and the symbiotic communities that form the intestinal microbiota. The inventors also demonstrated that hReg3α transgenic mice are better protected against DSS-induced colitis after antibiotic treatment.

[0021] Therefore, the present invention provides a Reg3α polypeptide for protecting oxygen-sensitive Gram-positive bacteria, which comprises the amino acid sequence of SEQ ID NO: 4 or a sequence at least 85% identical thereto.

[0022] Also provided is an in vivo or ex vivo method for protecting oxygen-sensitive Gram-positive bacteria, comprising contacting the oxygen-sensitive Gram-positive bacteria with a Reg3α polypeptide comprising the amino acid sequence of SEQ ID NO: 4 or a sequence at least 85% identical thereto.

[0023] As used herein, "Reg3α polypeptide" means regenerating islet-derived protein 3-α, which is a pancreatic secretory protein similar to the C-type lectin superfamily. In one embodiment, the Reg3α polypeptide is mammalian Reg3α, particularly primate (preferably human) or rodent (such as rat or mouse) Reg3α. Reg3α can be natural Reg3α or a naturally occurring or engineered variant thereof.

[0024] In the context of the present invention, the Reg3α polypeptide comprises the amino acid sequence SEQ ID NO:4 or a sequence at least 85% identical thereto. The amino acid sequence SEQ ID NO:4 is the sequence of mature hReg3α truncated by trypsin. According to one embodiment, the Reg3α polypeptide comprises the amino acid sequence SEQ ID NO:1 or a sequence at least 85% identical thereto. According to another embodiment, the Reg3α polypeptide comprises the amino acid sequence SEQ ID NO:2 or a sequence at least 85% identical thereto. According to another embodiment, the Reg3α polypeptide comprises the amino acid sequence SEQ ID NO:3 or a sequence at least 85% identical thereto.

[0025] The amino acid sequence SEQ ID NO: 1 is the sequence of hReg3α and its signal peptide (signal peptide corresponding to amino acids 1-26). In vivo, hReg3α of sequence SEQ ID NO: 1 is processed to remove the signal peptide and form mature hReg3α. Mature hReg3α has the amino acid sequence SEQ ID NO: 3.

[0026] Following proteolytic cleavage with trypsin, 11 amino acids are removed from the N-terminus of the mature protein Reg3α.

[0027] The amino acid sequence SEQ ID NO:4 is the sequence of the naturally occurring mature protein hReg3α after trypsin cleavage; it corresponds to SEQ ID NO:3, in which the 11 first amino acids have been deleted.

[0028] The amino acid sequence SEQ ID NO: 2 is the sequence of hReg3α, wherein the peptide signal sequence has been replaced by methionine. This sequence corresponds to the recombinant mature protein.

[0029] As used herein, the term "Reg3α polypeptide comprising its amino acid sequence" refers to a polypeptide comprising an amino acid sequence that is at least 85%, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to the amino acid sequence of SEQ ID NO: 4. In some embodiments, the polypeptide comprises an amino acid sequence that is at least 85%, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

[0030] Amino acid sequence identity is defined as the percentage of amino acid residues in a sequence that are identical to the amino acid residues in a reference sequence after aligning the sequences and, if necessary, introducing gaps to achieve maximum sequence identity percentage, and not considering any conservative substitutions as part of sequence identity. Sequence identity can be determined over the full length of the analyzed sequence, the full length of the reference sequence, or both. The identity percentage of a protein sequence can be calculated by, for example, using Needle, and using the BLOSUM62 matrix with a gap opening penalty of 10 and a gap extension penalty of 0.5, performing a paired global alignment based on the Needman-Wunsch alignment algorithm to find the best alignment (including gaps) of two sequences along their entire length.

[0031] According to one embodiment, the Reg3α polypeptide protects oxygen-sensitive Gram-positive bacteria from one or more of the following:

[0032] (i) Intestinal inflammation;

[0033] (ii) Exposure to oxygen, especially reactive oxygen species.

[0034] According to one embodiment, the Reg3α polypeptide allows for an increase in the survival and growth of butyrate-producing bacteria and the concentration of butyrate as an anti-inflammatory compound. Thus, the Reg3α polypeptide allows for a reduction in inflammation.

[0035] The term "oxygen-sensitive Gram-positive bacteria" as used herein refers to oxygen-sensitive Gram-positive bacteria, such as Gram-positive members of the Clostridiales order, preferably Gram-positive bacteria of the Ruminocaccaceae family and / or the Lachnospiraceae family, most preferably they are from the Faecalibacterium genus and / or the Roseburia genus, and more particularly they are Faecalibacterium prausnitzii and / or Roseburia intestinalis. In a preferred embodiment, the "oxygen-sensitive Gram-positive bacteria" are bacteria that produce butyrate. In a specific embodiment, the "oxygen-sensitive Gram-positive bacteria" are enteric bacteria known to produce butyrate.

[0036] Therapeutic applications

[0037] According to another aspect of the present invention, the Reg3α polypeptide as defined above is used for preventing or treating microbiota-associated diseases and / or disorders.

[0038] Also provided is a method for preventing or treating microbiota-associated diseases and / or disorders, comprising administering a Reg3α polypeptide as defined above to a host in need thereof.

[0039] As used herein, the term "prevention" refers to any method that partially or completely prevents or delays the onset of one or more symptoms or features of a microbiota-associated disease and / or disorder. Prevention can be administered to a subject who does not show signs of a microbiota-associated disease and / or disorder.

[0040] As used herein, the term "treatment" refers to any method for partially or completely alleviating, alleviating, inhibiting and / or reducing the incidence of one or more symptoms or characteristics and / or prolonging the life span of an individual suffering from a microbiota-related disease and / or disorder. In some embodiments, treatment may be administered to a subject who exhibits only early signs of a microbiota-related disease and / or disorder.

[0041] As used herein, a subject relates to an animal, and preferably to a mammal. More preferably, the subject is a rodent, and most preferably a mouse or a rat. In another embodiment of the invention, the subject is a primate and most preferably a human. The subject may be suspected of having a microbiota-related disease and / or disorder, or be at risk of developing a microbiota-related disease and / or disorder.

[0042] As used herein, the term "microbiome-related diseases and / or disorders" refers to diseases or disorders associated with microbiome imbalance and particularly with intestinal microbiome imbalance. "Microbiome-related diseases and / or disorders" refers to diseases or disorders selected from: inflammatory bowel disease (IBD), colitis, gastrointestinal infection, irritable bowel syndrome and other gastrointestinal functional diseases, gastrointestinal cancer, metabolic syndrome and obesity, diabetes, liver disease, allergic diseases, neurodegenerative diseases and psychological disorders. "Microbiome-related diseases and / or disorders" may also refer to diseases or disorders selected from: autoimmune diseases, cystic fibrosis, atopic dermatitis, neurological diseases (such as autism), anxiety, depression and chronic pain. Specifically, neurodegenerative diseases include Alzheimer's disease and Parkinson's disease. Microbiome-related diseases and / or disorders may be due to lifestyle stressors that destroy the balance of intestinal microbiome, such as various types of drugs, antibiotics, chemotherapy, radiotherapy, immunotherapy, malnutrition, eating disorders, disease, aging and / or heredity.

[0043] Reg3α peptide induced depletion of total Bacteriodetes (phylum Prevotellaceae), Sutterellaceae (phylum Proteobacteria), Porphyromonadaceae, and Bacteroidaceae (phylum Bacteroidetes) in the gut microbiota.

[0044] In the context of preventing or treating microbial-related diseases and / or disorders, the Reg3α polypeptide can be administered by any suitable route of administration, such as oral, intravenous, rectal, sublingual, mucosal, nasal, ocular, subcutaneous, intramuscular, transdermal, spinal, intrathecal, intraarticular, intraarterial, subarachnoid, bronchial or lymphatic administration. In a preferred embodiment, Reg3α is administered orally or via a mucosal route. In another preferred embodiment, Reg3α is administered by a rectal route.

[0045] Preferably, the Reg3α polypeptide is provided in the form of a pharmaceutical composition comprising the Reg3α polypeptide and at least one pharmaceutically acceptable excipient.

[0046] The pharmaceutical composition used in the context of the present invention is preferably designed to be suitable for the selected route of administration and, where appropriate, uses pharmaceutically acceptable diluents, carriers and / or excipients, such as dispersants, buffers, surfactants, preservatives, solubilizers, isotonic agents, stabilizers, etc.

[0047] As used herein, the term "pharmaceutically acceptable excipient" refers to any excipient suitable for use in contact with the tissues of a subject without undue toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0048] In another aspect, the present invention relates to a pharmaceutical composition for oral or transmucosal administration, or for oral or transmucosal administration, comprising a Reg3α polypeptide and at least one physiologically acceptable excipient. The pharmaceutical composition is intended for oral or transmucosal administration and therefore comprises at least one pharmaceutically acceptable excipient suitable for oral or transmucosal administration.

[0049] As used herein, the term "transmucosal administration" includes all types of administration through the mucosa, and includes, for example, rectal, tongue, lung, vaginal or nasal administration. Preferably, the type of administration can adapt to the type of microbiota-related diseases and / or disorders. In a preferred embodiment, the composition according to the present invention is used for oral or rectal administration, more preferably for rectal administration.

[0050] The pharmaceutical composition according to the present invention can be administered by transmucosal administration, and can be prepared into, for example, fast-dissolving tablets, emulsions, solutions, sprays, gels, mucoadhesive tablets or pastes, lozenges, sublingual tablets, drops, chewable tablets, suppositories or gums.

[0051] The pharmaceutical composition according to the present invention can be orally administered in the form of a suitable pharmaceutical unit dosage form. The pharmaceutical composition of the present invention can be prepared in a variety of forms, including tablets, hard or soft gelatin capsules, aqueous solutions, suspensions and liposomes and other sustained-release preparations, such as shaped polymer gels. The pharmaceutical composition of the present invention can be prepared in a gastric protection form, thereby allowing the Reg3α polypeptide to pass through the stomach and be released in the intestine.

[0052] The pharmaceutical composition according to the present invention can be administered by rectal administration. The pharmaceutical composition of the present invention can be prepared in various forms, including compositions in which the carrier is solid, for example as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and suppositories can be conveniently formed by mixing the pharmaceutical composition with one or more softened or molten carriers, followed by cooling and molding in a mold.

[0053] Each of these application forms can be produced by conventionally known formulation methods using formulation additives commonly used to produce such formulations. Such additives used in the formulations of the present invention may contain adjuvants or convenience agents, including solvents, buffers, flavorings, sweeteners, fillers, preservatives, gelling agents, carriers, diluents, surfactants and mucoadhesive polymers.

[0054] Preferred solvents which can be used according to the invention are alcohols, in particular ethanol, fatty acid esters, triglycerides, water and mixtures thereof.

[0055] Preferred preservatives are the lower alkyl parabens, especially methyl and propyl parabens.

[0056] Examples of suitable carriers and diluents include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, aqueous syrup, methylcellulose, methyl and propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.

[0057] As is well known in the medical arts, the dosage for any one subject depends on many factors, including the patient's size, body surface area, age, the specific compound being administered, sex, time and route of administration, general health, and other drugs being administered concurrently.

[0058] In another aspect, the present invention relates to a composition according to the present invention for use in preventing or treating microbiota associated diseases and / or disorders.

[0059] According to another aspect of the present invention, the Reg3α polypeptide or composition for oral or transmucosal administration according to the present invention is used to increase the amount of butyrate in the intestine.

[0060] Non-therapeutic applications

[0061] All previously mentioned definitions also apply to such non-therapeutic applications.

[0062] The present invention also relates to the use of the Reg3α polypeptide defined above for promoting the in vitro growth of oxygen-sensitive Gram-positive bacteria.

[0063] Also provided is a method for promoting the survival and / or growth of oxygen-sensitive Gram-positive bacteria in vitro, which comprises contacting the oxygen-sensitive Gram-positive bacteria with the Reg3α polypeptide as defined above.

[0064] Oxygen sensitive Gram-positive bacteria are preferably industrially interesting bacteria such as Bifidobacterium, lactic acid producing species or any Gram-positive bacteria. Probiotics are live microbial food additives that beneficially affect the host organism by improving its intestinal microbial balance. The beneficial effects of probiotics include strengthening the epithelial barrier, protecting from physiological stress, and regulating intestinal associated lymphoid tissue. Most probiotics, especially Bifidobacterium, are sensitive microorganisms with low survival rates to stress generated during food production, storage and consumption.

[0065] In one embodiment, these bacteria are of particular interest in the formulation of foods and / or dietary supplements.

[0066] In one embodiment, these bacteria are of particular interest for the production and / or degradation of complex organic molecules such as complex carbohydrates and milk proteins.

[0067] As used herein, the term "ex vivo viability and / or growth" includes viability and / or growth in a fermenter and / or a product such as a food (e.g. a dairy product). In fact, it is difficult to obtain high yields of oxygen-sensitive Gram-positive bacteria due to the presence of reactive oxygen species (ROS). The use of the polypeptides according to the invention allows the protection of oxygen-sensitive Gram-positive bacteria from oxidative stress and therefore allows higher yields to be obtained.

[0068] As used herein, the term "enhance" includes the possibility of obtaining higher yields of oxygen-sensitive Gram-positive bacteria, or culturing oxygen-sensitive Gram-positive bacteria using less stringent anaerobic conditions while obtaining similar bacterial yields as when using strict anaerobic conditions.

[0069] In another aspect, the invention relates to the use of a polypeptide as defined herein in the preparation of a food product, and in particular a dairy product.

[0070] Throughout this application, the term " include ” should be interpreted as covering all the specifically mentioned features as well as optional, additional, unspecified features. As used herein, the term “ include The use of " also discloses that no features are present except those specifically mentioned (i.e., " Composed of Furthermore, the indefinite article “a” or “an” does not exclude a plurality. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage.

[0071] The sequence of this application is as follows:

[0072] SEQ ID NO: 1:

[0073] MLPPMALPSVSWMLLSCLMLLSQVQGEEPQRELPSARIRCPKGSKAYGSHCYALFLSPKSWTDADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNSYSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFAWERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLPYVCKFTD

[0074] SEQ ID NO:2:

[0075] MEEPQRELPSARIRCPKGSKAYGSHCYALFLSPKSWTDADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNSYSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFAWERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLPYVCKFTD

[0076] SEQ ID NO:3:

[0077] EEPQRELPSARIRCPKGSKAYGSHCYALFLSPKSWTDADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNSYSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFAWERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLPYVCKFTDSEQ ID NO:4:

[0078] IRCPKGSKAYGSHCYALFLSPKSWTDADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNSYSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFAWERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLPYVCKFTD Sequence Listing <110> National Institute of Health and Medicine (INSTITUT NATIONAL DE LA SANTE ET LA ARECHERCHE MEDICALE (INSERM)) ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS INSTITUTE NATIONAL DE LA RECHERCHEAGRONOMIQUE (INRA) University of Paris-South <120> REG3α for protection of oxygen-sensitive Gram-positive bacteria <130> EFL20023F <150> EP17305925.4 <151> 2017-07-13 <160> 4 <170> SIPOSequenceListing 1.0 <210> 1 <211> 175 <212> PRT <213> Homo sapiens <400> 1 Met Leu Pro Pro Met Ala Leu Pro Ser Val Ser Trp Met Leu Leu Ser 1 5 10 15 Cys Leu Met Leu Leu Ser Gln Val Gln Gly Glu Glu Pro Gln Arg Glu 20 25 30 Leu Pro Ser Ala Arg Ile Arg Cys Pro Lys Gly Ser Lys Ala Tyr Gly 35 40 45 Ser His Cys Tyr Ala Leu Phe Leu Ser Pro Lys Ser Trp Thr Asp Ala 50 55 60 Asp Leu Ala Cys Gln Lys Arg Pro Ser Gly Asn Leu Val Ser Val Leu 65 70 75 80 Ser Gly Ala Glu Gly Ser Phe Val Ser Ser Leu Val Lys Ser Ile Gly 85 90 95 Asn Ser Tyr Ser Tyr Val Trp Ile Gly Leu His Asp Pro Thr Gln Gly 100 105 110 Thr Glu Pro Asn Gly Glu Gly Trp Glu Trp Ser Ser Ser Asp Val Met 115 120 125 Asn Tyr Phe Ala Trp Glu Arg Asn Pro Ser Thr Ile Ser Ser Pro Gly 130 135 140 His Cys Ala Ser Leu Ser Arg Ser Thr Ala Phe Leu Arg Trp Lys Asp 145 150 155 160 Tyr Asn Cys Asn Val Arg Leu Pro Tyr Val Cys Lys Phe Thr Asp 165 170 175 <210> 2 <211> 150 <212> PRT <213> Artificial Sequence <220> <223> recombinant form <400> 2 Met Glu Glu Pro Gln Arg Glu Leu Pro Ser Ala Arg Ile Arg Cys Pro 1 5 10 15 Lys Gly Ser Lys Ala Tyr Gly Ser His Cys Tyr Ala Leu Phe Leu Ser 20 25 30 Pro Lys Ser Trp Thr Asp Ala Asp Leu Ala Cys Gln Lys Arg Pro Ser 35 40 45 Gly Asn Leu Val Ser Val Leu Ser Gly Ala Glu Gly Ser Phe Val Ser 50 55 60 Ser Leu Val Lys Ser Ile Gly Asn Ser Tyr Ser Tyr Val Trp Ile Gly 65 70 75 80 Leu His Asp Pro Thr Gln Gly Thr Glu Pro Asn Gly Glu Gly Trp Glu 85 90 95 Trp Ser Ser Ser Asp Val Met Asn Tyr Phe Ala Trp Glu Arg Asn Pro 100 105 110 Ser Thr Ile Ser Ser Pro Gly His Cys Ala Ser Leu Ser Arg Ser Thr 115 120 125 Ala Phe Leu Arg Trp Lys Asp Tyr Asn Cys Asn Val Arg Leu Pro Tyr 130 135 140 Val Cys Lys Phe Thr Asp 145 150 <210> 3 <211> 149 <212> PRT <213> Homo sapiens <400> 3 Glu Glu Pro Gln Arg Glu Leu Pro Ser Ala Arg Ile Arg Cys Pro Lys 1 5 10 15 Gly Ser Lys Ala Tyr Gly Ser His Cys Tyr Ala Leu Phe Leu Ser Pro 20 25 30 Lys Ser Trp Thr Asp Ala Asp Leu Ala Cys Gln Lys Arg Pro Ser Gly 35 40 45 Asn Leu Val Ser Val Leu Ser Gly Ala Glu Gly Ser Phe Val Ser Ser 50 55 60 Leu Val Lys Ser Ile Gly Asn Ser Tyr Ser Tyr Val Trp Ile Gly Leu 65 70 75 80 His Asp Pro Thr Gln Gly Thr Glu Pro Asn Gly Glu Gly Trp Glu Trp 85 90 95 Ser Ser Ser Asp Val Met Asn Tyr Phe Ala Trp Glu Arg Asn Pro Ser 100 105 110 Thr Ile Ser Ser Pro Gly His Cys Ala Ser Leu Ser Arg Ser Thr Ala 115 120 125 Phe Leu Arg Trp Lys Asp Tyr Asn Cys Asn Val Arg Leu Pro Tyr Val 130 135 140 Cys Lys Phe Thr Asp 145 <210> 4 <211> 138 <212> PRT <213> Homo sapiens <400> 4 Ile Arg Cys Pro Lys Gly Ser Lys Ala Tyr Gly Ser His Cys Tyr Ala 1 5 10 15 Leu Phe Leu Ser Pro Lys Ser Trp Thr Asp Ala Asp Leu Ala Cys Gln 20 25 30 Lys Arg Pro Ser Gly Asn Leu Val Ser Val Leu Ser Gly Ala Glu Gly 35 40 45 Ser Phe Val Ser Ser Leu Val Lys Ser Ile Gly Asn Ser Tyr Ser Tyr 50 55 60 Val Trp Ile Gly Leu His Asp Pro Thr Gln Gly Thr Glu Pro Asn Gly 65 70 75 80 Glu Gly Trp Glu Trp Ser Ser Ser Asp Val Met Asn Tyr Phe Ala Trp 85 90 95 Glu Arg Asn Pro Ser Thr Ile Ser Ser Pro Gly His Cys Ala Ser Leu 100 105 110 Ser Arg Ser Thr Ala Phe Leu Arg Trp Lys Asp Tyr Asn Cys Asn Val 115 120 125 Arg Leu Pro Tyr Val Cys Lys Phe Thr Asp 130 135

Brief Description of the Drawings

[0079] The present invention will be further illustrated by the following figures and examples.

[0080] Attached photos

[0081] Figure 1 : Serum concentrations of human Reg3α and murine Reg3y in wild-type (WT) and hReg3α transgenic (hReg3a) mice before (control) and after (colitis) treatment with DSS (n=6).

[0082] Figure 2 : Relative abundance of bacterial families in hReg3a transgenic (n=5) and WT (n=7) mice at basal state (control) and on day 12 after initial exposure to DSS (colitis).

[0083] Figure 3 : Normalized CFU (colony forming units) counts of Gram-positive enteric Roseburia and Faecalibacterium prausnitzii in strictly anaerobic culture.

[0084] Figure 4 :Normalized CFU counts of Gram-positive enteric Roseburia and Faecalibacterium prausnitzii after exposure to ambient air.

[0085] exist Figure 3 and Figure 4 In the , the number of CFU was normalized to the mean number of CFU measured in the control culture (buffer). The assay was performed in quadruplicate in two independent experiments. Data are mean values ​​with SEM. Two-sided Wilcoxon rank sum test was performed for analysis. *P<0.05, ***P<0.001.

[0086] Figure 5 : Evolution of body weight changes due to DSS-induced colitis in hReg3α transgenic mice (hReg3α) and wild-type (WT) mice (n=20 per group; 2 independent experiments). Bold line: 5-day period of DSS administration.

[0087] Figure 6 : Evolution of rectal bleeding scores due to DSS-induced colitis in hReg3α transgenic mice (hReg3α) and wild-type (WT) mice (n=20 per group; 2 independent experiments). Bold line: 5-day period of DSS administration.

[0088] Figure 7 : Evolution of diarrhea scores due to DSS-induced colitis in hReg3α transgenic mice (hReg3α) and wild-type (WT) mice (n=20 per group; 2 independent experiments). Bold line: 5-day period of DSS administration.

[0089] Figure 8 : Histological evaluation of intestinal epithelium (n=14 per group).

[0090] Fig. 9 : mRNA expression levels of the indicated inflammatory markers in colonic epithelial cells of WT and hReg3α transgenic mice (n=5). Data are mean±SEM. Two-sided Wilcoxon rank sum test was performed for analysis. *P<0.05, **P<0.01, ***P<0.001.

[0091] Fig.10 : Histological evaluation of the colon and distal colon of mice during DSS-induced colitis. WT+rcHIP corresponds to WT mice treated with 4.2 μg recombinant hReg3α (rc-hReg3α) / g mouse / day intravenous administration. hReg3a corresponds to hReg3α transgenic mice. Data are mean ± SEM. Histological scoring is based on the evaluation of mucosal architectural changes, mononuclear cell infiltration, neutrophil infiltration, epithelial defects, and goblet cell loss.

[0092] Fig.11 :Evolution of fecal blood scores due to DSS-induced colitis in hReg3α transgenic (hReg3α) and WT+rcHIP mice. Bold line: 5-day period of DSS administration.

[0093] Fig.12 : Evolution of diarrhea scores due to DSS-induced colitis in hReg3α transgenic (hReg3α) and WT+rcHIP mice. Bold line: 5-day period of DSS administration.

[0094] Fig.13 : Evolution of body weight changes due to DSS-induced colitis in hReg3α transgenic (hReg3α) and WT+rcHIP mice. Bold line: 5-day period of DSS administration.

[0095] Fig.14 : Evolution of body weight changes due to DSS-induced colitis in TG Abx, WT Abx, TG, and WT mice.

[0096] TG mice correspond to hReg3α transgenic mice that were not treated with antibiotics. WT mice correspond to wild-type mice that were not treated with antibiotics. TG Abx correspond to hReg3α transgenic mice that were treated with antibiotics. WT Abx mice correspond to WT mice that were treated with antibiotics.

[0097] The death of mice is indicated by a cross on the graph.

[0098] Fig.15 : Evolution of fecal blood scores due to DSS-induced colitis in TG Abx, WT Abx, TG, and WT mice.

[0099] The death of mice is indicated by a cross on the graph.

[0100] Fig.16 : Histological evaluation of the distal colon of mice during DSS-induced colitis in TG Abx, WT Abx, TG, and WT mice. [Example]

[0101] Example 1: Delivery of human Reg3α into the intestinal lumen alters the composition of the gut microbiota in hepatocyte-targeted Reg3α transgenic mice

[0102] We investigated the effects of human Reg3α (hReg3α) on the composition of the gut microbiota and gut barrier integrity in hReg3α transgenic mice under homeostatic and inflammatory conditions. Inflammation was induced by oral absorption of dextran sulfate sodium (DSS). To prevent hReg3α protein degradation by acid and luminal proteases in the upper GIT, we used previously generated homozygous transgenic C57BL / 6 mice that express hReg3α in hepatocytes under the control of the mouse albumin gene promoter and showed that in these mice, hReg3α protein is secreted into the bile ducts and the gastrointestinal tract (GIT) lumen. Transgenic hepatocytes secrete hReg3α into the blood vessels through the basolateral membrane and into the bile canaliculi through the apical membrane.

[0103] The expression levels of endogenous Reg3β and Reg3γ in blood and colon tissue were negligible in wild-type (WT) mice at basal state but were high as expected in DSS-treated WT mice ( Figure 1 In hReg3α transgenic mice, similarly high serum hReg3α levels were found in both basal and inflammatory states ( Figure 1 ). This level was of the same order of magnitude as endogenous Reg3 in DSS-treated WT mice. In both basal and inflammatory states, colonic expression levels of endogenous Reg3 mRNA were negligible in hReg3α transgenic mice. In other words, during DSS-induced colitis, hReg3α transgenic mice did not display any upregulation of Reg3β or Reg3γ (probably because they are counter-controlled by overexpressed hReg3α), implying that Reg3β and Reg3γ play a negligible role in the disease phenotype and gut microbiota composition exhibited by hReg3α transgenic mice.

[0104] Next, we analyzed the composition of the fecal microbiota of healthy and DSS-treated hReg3α transgenic mice using MiSeq 16S rDNA gene sequencing. Control WT and hReg3α transgenic mice were bred and processed under the same conditions. Principal component analysis (PCA) showed that hReg3α transgenic mice and WT mice had two clearly separated clusters at the family level before (P=0.001) and after (P=0.039) exposure to DSS. Twelve bacterial families showed significant differences in their relative abundance between hReg3α transgenic mice and WT mice in both the basal and inflammatory states ( Figure 2). In the basal state of hReg3α transgenic mice, Clostridiaceae (Proteobacteria), Prevotellaceae, Porphyromonadaceae, and Bacteroidetes (Bacteroidetes) were underrepresented, while Lachnospiraceae and unclassified Clostridium (Firmicutes) were overrepresented. The same changes in microbial composition were also found at the genus level. In the inflammatory state, WT mice showed increases in Prevotellaceae and Bacteroidetes, and decreases in all other families mentioned above. hReg3α transgenic mice behaved similarly, with the exception of Prevotellaceae, whose levels remained low; and Ruminococcaceae (Clostridales), whose levels increased dramatically ( Figure 2 ).

[0105] The gut microbiota composition we observed in homozygous transgenic (hReg3α-TG+ / +) mice could be due to the Reg3α transgene or epigenetic effects. To address this question, we studied the temporal evolution of the initial WT microbiota in heterozygous transgenic (hReg3α-TG+ / -) pups born to WT mothers. The fecal microbiota of 15 hReg3α-TG+ / - pups from three different litters and cages was sequenced at 9 and 12 weeks of age and compared with their WT dams (n=3) and unrelated WT mice of similar age (n=11). The fecal microbiota of twelve hReg3α-TG+ / + mice was also analyzed for comparison. Family-level PCA (principal component analysis) plots showed that at week 9, the microbiota from hReg3α-TG+ / - mice was classified between the microbiota from (maternal and unrelated) WT and hReg3α-TG+ / + mice (hReg3α-TG+ / - vs. WT and hReg3α-TG+ / - vs. hReg3α-TG+ / +, P<0.01) and moved close to the microbiota from hReg3α-TG+ / + mice in the next three weeks (hReg3α-TG+ / - vs. WT, P<0.001; hReg3α-TG+ / - vs. hReg3α-TG+ / +, P>0.05). The altered microbiota composition of hReg3α-TG+ / - mice consisted mainly of a decrease in Prevotellaceae, Clostridiaceae, and Verrucomicrobiaceae and an increase in Lachnospiraceae and Ruminococcaceae to reach levels comparable to those of hReg3α-TG+ / + mice after 12 weeks. Thus, the WT microbiota of heterozygous newborn mice evolved into a transgene-positive microbiota within a few months, implying that the Reg3α transgene effect replaced maternal inheritance.

[0106] Reg3α increases the viability of some highly oxygen-sensitive Clostridia

[0107] The altered composition of the microbiota in hReg3α transgenic mice corresponded to a large increase in the ratio between Gram-positive and Gram-negative bacteria, which is difficult to reconcile with the reported selective anti-Gram-positive bactericidal activity of hReg3α. We speculated that the antioxidant activity of hReg3α is a key factor in the altered gut microbial ecology in hReg3α transgenic mice. The mechanism at play would be the selective pressure exerted by hReg3α, favoring strictly anaerobic Gram-positive bacteria, as are some Clostridia. To confirm this idea, we tested the antioxidant efficiency of the full-length recombinant human Reg3α protein (rcReg3α) in prokaryotic cells in vitro. The recombinant protein we used has chemical and biological activity with respect to anti-inflammatory properties and carbohydrate binding selectivity in eukaryotic cells. We first cultured Enterococcus faecalis, a Gram-positive enteric commensal bacterium, and subjected it to a ROS-generating agent (paraquat) during the exponential phase of growth. Exposure to 200 mM paraquat had a strong bactericidal effect on E. faecalis. Addition of 10 μM rcReg3α restored exponential growth of E. faecalis, indicating that ROS generated by paraquat were effectively reduced in the presence of rcReg3α. This was confirmed by flow cytometric measurements using the ROS-specific fluorescent probe H2-DCFDA and propidium iodide DNA staining. We found some bacterial aggregation, but rcReg3α had no bactericidal effect on E. faecalis, which is different from previous reports. This discrepancy may be strain-dependent, but note that the lack of Reg3α bactericidal activity is consistent with the enrichment of Gram-positive bacteria we observed in the gut microbiota of transgenic mice.

[0108] We next turned to cultures of two well-documented extremely oxygen-sensitive Gram-positive bacterial species, enteric Roseburia (Lachnospiraceae, Clostridial cluster XIVa) and Faecalibacterium prausnitzii (Ruminococcus family, Clostridial cluster IV), which are major producers of butyrate and anti-inflammatory compounds in the human gut microbiota and whose abundance is significantly reduced during IBD. Enteric Roseburia is known to survive less than 2 min when exposed to air on the surface of an agar plate. Faecalibacterium prausnitzii is even more sensitive to air exposure than enteric Roseburia, growing slowly under anaerobic conditions and becoming microaerotolerant in the presence of antioxidants via a mechanism of electron transfer to oxygen. We performed anaerobic cultures of enteric Roseburia and Faecalibacterium prausnitzii with or without subsequent exposure to ambient air for 5 min. We found that rcReg3α had a significant growth-promoting effect on Faecalibacterium prausnitzii under strictly anaerobic conditions and a survival effect on both bacteria after exposure to oxygen ( Figure 3 and 4prausnitzii anaerobic cultures incubated with rcReg3α for 24 h were centrifuged and subsequently immunoblotted with anti-Reg3α, revealing that 15-kDa rcReg3α co-precipitated with bacterial aggregates. Slide imaging revealed that F. prausnitzii incubated with rcReg3α survived after 2 h of exposure to ambient air, whereas control cultures completely lysed. These findings confirm that rcReg3α possesses potent antioxidant activity against prokaryotic cells and is able to enhance the viability and growth of several commensal Clostridia that are extremely oxygen-sensitive. They support our hypothesis that the ROS scavenger activity of hReg3α critically contributes to the alterations in the gut microbiota observed in hReg3α transgenic mice.

[0109] hReg3α transgenic mice are completely protected against DSS-induced colitis

[0110] The main features of the dysbiotic microbiota in IBD patients are an increase in Clostridiaceae, Prevotellaceae, and Enterobacteriaceae (Proteobacteria) and a decrease in Ruminococcaceae and Lachnospiraceae (which include major butyrate-producing commensals). Similar alterations in the composition of the gut microbiota have also been associated with colitis in genetically susceptible mouse models. The fact that more or less reverse alterations occurred in the gut microbiota of hReg3α transgenic mice suggests that the microbiota shaped by hReg3α may have beneficial effects on health.

[0111] To test this idea, we studied the response to induced colitis in hReg3α transgenic mice and then performed co-housing and fecal transplant experiments. Homozygous hReg3α transgenic mice received oral administration of 3% DSS for 5 days, followed by normal drinking water for 7 days. A control group of WT mice was bred and processed under the same conditions. Body weight changes, stool hardness, and bleeding scores and survival were monitored over time. Histopathological features were scored on day 12. Strikingly, DSS-treated hReg3α transgenic mice showed only minimal signs of acute colitis. Compared with WT mice, they had reduced weight loss, diarrhea, and rectal bleeding, and a 100% survival rate on day 12, compared with 70% survival rate of WT mice ( Figure 5-7 Their colons displayed less barrier defects as well as less goblet cell loss and inflammatory cell infiltration than those of WT mice ( Figure 8). 12-week-old heterozygous hReg3α transgenic mice born to WT mothers were also exposed to DSS, and we found that they exhibited relatively benign colitis, consistent with the fact that their intestinal microbiota was compositionally and, therefore, functionally similar to that of homozygous transgenic mice. We ensured that the hReg3α lectin did not interact with dextran in vitro, consistent with previous reports, and therefore, the observed phenotype could not be attributed to direct blockade of DSS toxicity by hReg3α. Positron emission tomography (PET) imaging using 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), a tracer of abnormally high glucose metabolism in inflammatory areas, was used to quantify intestinal inflammation. Colonic [18F]FDG uptake increased over time in DSS-treated WT mice, while remaining weak (i.e., compared to that seen in untreated mice) in hReg3α transgenic mice (P=0.013 over the d7-d12 period). The severity of DSS-induced colitis was also assessed by measuring the colonic expression levels of inflammatory markers (IL1α, IL1β, TNFα, IL6, CXCL1, CCL3, CCL9). Most of them showed a significant increase in DSS administration in WT mice but not in hReg3α transgenic mice ( Fig. 9). We investigated the integrity of the intestinal mucosal barrier in healthy and DSS-treated hReg3α transgenic mice using immunostaining for Muc2 mucin and 16S rRNA FISH, transcriptome profiling, and gene set enrichment analysis (GSEA) using the KEGG and Reactome databases. In the basal state, the light microscopy images of the mucosal barrier in hReg3α transgenic and WT mice were similar. However, several pathways associated with the intestinal barrier, including regulators of cell-matrix interactions and mucin O-glycosylation, were upregulated in hReg3α transgenic mice. During intestinal inflammation, the colonic mucosal barrier in hReg3α transgenic mice remained intact over a considerable area, whereas in WT mice, most of it was disrupted, allowing bacterial colonization in the epithelium. The functional robustness of the mucosal barrier in hReg3α transgenic mice compared with WT mice was further emphasized as follows. Upregulation of several tight junction genes involved in regulating cell-cell interactions was observed. Wheat germ agglutinin (WGA) immunoblotting showed increased O-glycosylation of epithelial mucins. As shown by 16S rRNA FISH analysis, bacterial translocation levels in mesenteric lymph nodes remained low. Unsupervised analysis of transcriptome profiles revealed that gene sets associated with lipopolysaccharide endotoxin (LPS) pathway activation were downregulated in DSS-treated hReg3α transgenic mice, with their profiles clustering with those of non-DSS-treated mice. Consistent with this, the increase in inflammation-related serum markers (LPS, soluble CD14) in these mice remained very small during intestinal inflammation. Finally, the concentration of malondialdehyde (MDA), a biomarker of oxidative stress, was significantly reduced in colon tissues of DSS-treated hReg3α transgenic mice compared with WT mice, providing in vivo evidence that the intestinal epithelium greatly benefits from the antioxidant properties of hReg3α during acute colitis.

[0112] Anti-inflammatory properties of the gut microbiota shaped by hReg3α promote survival of colonized wild-type mice against DSS-induced colitis

[0113] To evaluate the protective effect of the hReg3α-type microbiota against colitis, we transferred the fecal microbiota from hReg3α transgenic mice to WT mice by co-housing. WT mice weaned at 3 weeks of age were co-housed with age-matched hReg3α transgenic mice for 8 weeks and then treated with DSS. The control group consisted of WT mice housed individually. At the end of the co-housing period, co-housed WT (CoH-WT) mice exhibited a significant shift in the gut microbiota composition toward the hReg3α transgenic pattern at the bacterial family level and significantly alleviated DSS-induced colitis in terms of stool hardness and bleeding, intestinal barrier integrity, and survival.

[0114] Next, we colonized germ-free C57BL / 6 mice with fecal microbiota from hReg3α transgenic or WT mice for 3 weeks. At the end of this period, fecal microbiota was analyzed by sequencing (day 0), and DSS treatment of colonized mice was then started. At D0, the microbiota of colonized hReg3α transgenic (ExGF-TG) and WT (ExGF-WT) mice drifted somewhat from their respective inocula. However, the microbiota of ExGF-TG mice still contained the same major bacterial communities as the inoculum, although the relative abundance values ​​were different and far from those of ExGF-WT mice. After DSS treatment, ExGF-TG mice survived with complete colitis, while 37% of ExGF-WT mice died, despite transient signs of colitis, particularly diarrhea and barrier defects. This was associated with a reduction in TLR4 signaling activation and expression levels of colonic inflammatory markers in the colon and a reduction in inflammatory responses in terms of LPS-induced endotoxemia.

[0115] Collectively, these results suggest that the hReg3α-shaped microbiota has a transmissible prosurvival effect, likely due to a reduced inflammatory response in the intestinal epithelium and reduced systemic dissemination of Gram-negative LPS. This is consistent with the depletion of potentially invasive Gram-negative bacteria we observed in the hReg3α-shaped gut microbiota. Indeed, clinical and histological signs of colitis were partially reduced in CoH-WT and ExGF-TG mice and completely abrogated in hReg3α transgenic mice, suggesting that, in the latter, a direct interaction between overexpressed hReg3α and the host contributes to the maintenance of intestinal barrier homeostasis and the anti-inflammatory effects of the hReg3α-shaped gut microbiota.

[0116] discuss

[0117] It is generally accepted that intestinal innate immune molecules play important roles in intestinal barrier function and gut microbiota homeostasis through their pleiotropic activities. It is also widely believed that impairment of their functional expression is a key contributor to chronic inflammatory bowel disease, as it disrupts the symbiotic interaction between gut microbes and the gut epithelial barrier. However, whether their manipulation contributes to the maintenance of host-microbiota homeostasis and, thereby, protects against intestinal inflammation remains to be determined. In this study, we demonstrated that increased luminal concentrations of hReg3α lectin in transgenic mice induced significant changes in the composition of the gut microbiota and significantly improved host resistance to intestinal inflammation. In fact, hReg3α transgenic mice exposed to DSS showed almost no signs of colitis, maintained a tight mucosal barrier, and achieved complete survival. We found that inflammatory responses and oxidative stress were significantly reduced in the colonic epithelium of DSS-treated hReg3α transgenic mice compared with WT mice, suggesting that hReg3α has potent antioxidant activity on intestinal epithelial cells during colitis. Our in vitro studies also demonstrated that the ROS-scavenging activity of recombinant human Reg3α (rcReg3α) acts on prokaryotic cells, particularly by promoting the survival of hyperoxia-sensitive bacteria.

[0118] The microbial changes exhibited by homozygous hReg3α transgenic mice under steady-state and inflammatory conditions mainly involved enrichment of Clostridia (Ruminococcus family, Lachnospiraceae) and depletion of Bacteroidetes (Prevotella family). hReg3α heterozygous mice, which contained a wild-type maternal microbiota at birth, gradually acquired a gut microbiota composition close to that of homozygous hReg3α transgenic mice—demonstrating the ability of hReg3α to shape the gut microbiota—and then exhibited colitis resistance similar to that of homozygous mice. Transfer of the hReg3α-type microbiota into wild-type mice exposed to DSS resulted in less severe disease, less pronounced dissemination of LPS in the blood, and improved survival, thus establishing the beneficial nature of the changes in microbiota composition induced by hReg3α. However, the fact that the transfer experiments did not fully convey phenotypic resistance suggests that hReg3α also exerts its effects in hReg3α transgenic mice by other means, most likely through direct antioxidant mucosal effects. As intravenous administration of rcReg3α did not ameliorate DSS-induced colitis in WT mice, a systemic anti-colitis effect can be abandoned. Thus, hReg3α provides protection against oxidative stress to both the intestinal epithelium and the commensal communities that form the gut microbiota. Future studies will be necessary to determine the location of sites involved in the ROS scavenging activity of hReg3α.

[0119] Since oxygen tolerance varies widely among intestinal bacteria, the broad-spectrum antioxidant activity of hReg3α may alter the balance between different bacterial communities. Our results suggest that in our mouse model, some highly oxygen-sensitive commensal bacteria respond to the presence of exogenous antioxidants such as hReg3α, which confers them a selective advantage over oxygen-tolerant anaerobic bacteria (i.e., those that are able to mount their own effective adaptive responses to oxygen toxicity). In this hypothesis, hReg3α would shape the intestinal microbiota at steady state through its antioxidant activity against environmental stressors present in the healthy mouse intestine and continue to exert this role under inflammation and oxidative stress. This notion is supported by the fact that Reg3α enhanced the growth of highly oxygen-sensitive commensal bacteria belonging to the order Clostridiales (Ruminococcus family, Lachnospiraceae). The enrichment of such commensals that produce anti-inflammatory molecules could trigger a benign process by improving the intestinal barrier function, which feeds back to maintain the commensal bacterial balance due to the reduction in ROS production. Conversely, an increase in Gram-negative commensal bacteria may trigger macrophage activation, increase ROS production, and amplify mucosal damage and dysbiosis in favor of aerobic commensals. Our results suggest that the stress imposed by hReg3α on the gut microbiota triggers such beneficial changes in composition and function.

[0120] From a clinical perspective, our findings suggest that modulation of the intraluminal concentration of Reg3α, such as by colon-targeted delivery of recombinant Reg3α, may be a valuable approach to mitigate intestinal inflammation through gut microbiota remodeling. Regarding potential benefits to patients, this approach would be a more physiological and non-toxic strategy for treating inflammatory flare-ups compared to current therapies including fecal transplants. Furthermore, it may be most successful at an early stage of the inflammatory process, or even before inflammation has started, and may therefore be useful for maintaining medically or surgically induced remission, and even preventing IBD in high-risk individuals.

[0121] Embodiment 2:

[0122] In contrast to hReg3α transgenic mice, intravenous administration of rcReg3α failed to ameliorate DSS-induced colitis in WT mice

[0123] We investigated the effects of daily intravenous administration of 4.2 μg of recombinant human Reg3α (rcReg3α) to WT mice under inflammatory conditions. Inflammation was induced by oral absorption of dextran sulfate sodium (DSS). These results were compared with homozygous transgenic C57BL / 6 mice expressing hReg3α in hepatocytes under the control of the mouse albumin gene promoter. Transgenic hepatocytes secreted hReg3α into blood vessels through the basolateral membrane and into bile canaliculi through the apical membrane.

[0124] The histological scores of the colon and distal colon were evaluated in both groups based on the assessment of mucosal architectural changes, mononuclear cell infiltration, neutrophil infiltration, epithelial defects, and goblet cell loss (results are shown in Table 2). Fig.10 WT mice treated with recombinant hReg3α had greater severity of inflammation than hReg3α transgenic mice. These results were particularly pronounced in the distal colon. hReg3α transgenic mice also had reduced fecal blood scores, diarrhea scores, and weight loss compared to treated WT mice ( Figure 11-13 ), resulting in a higher survival rate in transgenic mice (100%) than in treated WT mice (30%).

[0125] Our findings suggest that modulating the intraluminal concentration of Reg3α effectively reduces intestinal inflammation through remodeling of the intestinal microbiota and has a better effect than intravenous administration of Reg3α. Therefore, administration of recombinant human Reg3α into the digestive tract is a preferred mode of administration as it may lead to better efficacy with less invasive administration.

[0126] Embodiment 3:

[0127] hReg3α transgenic mice are better protected against DSS-induced colitis after antibiotic treatment

[0128] Antibiotic degradation of the microbiota leads to increased inflammation and causes many intestinal and extraintestinal deleterious effects. We studied the effects of two antibiotics (named Abx), vancomycin and gentamicin, administered over a three-day period, on the following response of WT mice and hReg3α transgenic mice to DSS-induced colitis. Vancomycin is a tricyclic glycopeptide that kills most Gram-positive organisms by binding to the bacterial cell wall and altering cell membrane permeability. It also interferes with bacterial RNA synthesis. Gentamycin is a broad-spectrum aminoglycoside antibiotic that targets aerobic Gram-negative bacilli.

[0129] In two independent experiments, we observed reduced weight loss and diarrhea scores in Abx transgenic (TG Abx) mice compared to Abx wild-type mice (WT Abx) and even compared to WT mice that did not receive antibiotic treatment (WT) (see e.g. Fig.14 ). Fecal blood scores were also reduced in Abx transgenic mice compared to WT Abx mice (see Fig.15 Analysis of the distal colon from Abx-treated transgenic mice on DSS showed significantly less inflammation and mucosal damage, which was significantly reduced compared with Abx-treated WT mice (see Fig.16 These results suggest that antibiotic interference with the Reg3α-type microbiota fails to disrupt intestinal homeostasis and the integrity of intestinal defense, which prevents intestinal inflammation.

[0130] Embodiment 4:

[0131] Intracolonic administration of hReg3α reduces colonic injury and inflammation in WT mice with colitis

[0132] We evaluated the effects of intrarectal administration of rcReg3α on colitis in WT mice. 100 μg of rcReg3α (rcReg3α; n=14) or an equal volume of buffer (n=15) was delivered one day before and on the day of trinitrobenzenesulfonic acid (TNBS) administration.

[0133] In fact, an alternative type of colitis can be induced using a single rectal administration of trinitrobenzene sulfonic acid (TNBS) and ethanol. In contrast to oral administration of DSS, which destroys colonic epithelial cells, alters barrier function, and subsequently causes inflammation, TNBS rapidly triggers severe colonic inflammation through T cell immune responses against haptenic proteins and luminal antigens.

[0134] Weight loss was similar in both groups of mice. Histological staining revealed that mice given intrarectal rcReg3α displayed milder colonic barrier defects and inflammation than mice not given intrarectal rcReg3α. Significant reductions in inflammatory markers Il1b, Tnf, and myeloperoxidase were observed in colon tissues of mice given intrarectal rcReg3α. These positive effects of topically administered recombinant Reg3α protein suggest that exogenous hReg3α can contribute to the maintenance of intestinal barrier integrity during colitis and underscore the health relevance of this molecule.

[0135] Repeated intravenous administration of rcReg3α was ineffective, whereas rectal administration of rcReg3α helped maintain intestinal barrier integrity during induction of colitis in control mice.

[0136] Thus, hReg3α provides protection against inflammation and oxidative stress to both the intestinal epithelium and the commensal communities that form the gut microbiota.

Claims

1. A use of a Reg3α polypeptide, wherein the Reg3α polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, for promoting the in vitro growth of oxygen-sensitive Gram-positive bacteria, wherein the oxygen-sensitive bacteria are members of the order Clostridiales, belonging to: the family Ruminococcaceae and / or the family Lachnospiraceae; or Faecalibacterium prausnitzii and / or Roseburia intestinalis.